Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM

被引:1
|
作者
Zach, Leor [1 ,4 ]
Agami, Amir [4 ,5 ]
Furman, Orit [1 ]
Attia, Moshe [3 ,4 ]
Cohen, Zvi [3 ,4 ]
Mizrachi, Iris Ben-Bassat [2 ]
Tam, Guy [2 ]
Zibly, Zion [3 ,4 ]
Nissim, Ouzi [3 ,4 ]
Spiegelmann, Roberto [3 ,4 ]
Huna-Baron, Ruth [2 ,4 ]
机构
[1] Sheba Med Ctr, Neurooncol Unit, Ramat Gan, Israel
[2] Sheba Med Ctr, Neuroophthalmol Serv, Ramat Gan, Israel
[3] Sheba Med Ctr, Neurosurg Dept, Ramat Gan, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Galilee Med Ctr, Nahariyya, Israel
关键词
MULTISESSION RADIOSURGERY; NORMAL TISSUE; MENINGIOMAS; TOLERANCE; NERVES;
D O I
10.1186/s13014-021-01879-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Most anterior visual pathway meningiomas (AVPM) are benign and slow-growing, but these tumors may affect visual functions, including visual acuity (VA) and visual field (VF). Due to location, most are treated non-surgically by fractionated stereotactic radiotherapy (FSRT), aiming to prevent tumor progression and visual functions deterioration. Unfortunately, FSRT in itself may affect visual functions. The current preferred treatment regimen (in terms of safety and effectiveness) is undetermined. While most cases are treated with conventional fractionation (cFSRT)-50.4-54 Gy in 28-30 fractions of 1.8-2 Gy, advances in technology have allowed shortening of total treatment length to hypofractionation (hSRT)-25-27 Gy in 3-5 fractions of 5-9 Gy. Our aim was to evaluate the association of radiotherapy regimen for treating AVPM (cFSRT vs. hSRT) with visual function outcomes (VA, VF) at the last neuro-ophthalmologic evaluation. Methods We conducted a retrospective cohort study of AVPM cases treated at Sheba Medical Center during 2004-2015. We compared cFSRT and hSRT regimens regarding visual function (VA, VF) outcomes at the last neuro-ophthalmologic evaluation. VA was determined by the logarithm of the minimum angle of resolution (LogMAR). VF was determined by the mean deviation (MD). A clinically relevant change in VA was defined as 0.2 LogMAR. Results 48 patients (13 receiving hSRT, 35 receiving cFSRT) were included, with a median follow-up of 55 months. No significant difference was evident regarding LogMAR or MD of involved eyes at the last evaluation. Six (17%) patients in the cFSRT group experienced clinically relevant VA deterioration in the involved eye, compared with six (46%) in hSRT (p = 0.06). Conclusion Our findings, using comprehensive and meticulous investigation of visual outcomes, suggest that hSRT may be associated with higher risk for VA and VF deterioration in AVPM especially in ONSM. We recommend the use of cFSRT for ONSM.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Image-guided hypo-fractionated stereotactic radiosurgery to spinal lesions - Comments
    Bilsky, MH
    Gutin, PH
    Yamada, Y
    Kondziolka, D
    NEUROSURGERY, 2001, 49 (04) : 846 - 846
  • [32] Hypo-fractionated radiotherapy with SpaceOAR for prostate cancer treated with Radixact TomoTherapy
    Can, S.
    Karacetin, D.
    Tatli, H.
    Atilla, O.
    Nalbant, N.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1546 - S1548
  • [33] Central hepatobiliary toxicity after liver SBRT and hypo-fractionated Radiotherapy
    Gkika, E.
    Weis, C.
    Kirste, S.
    Mohammad, F.
    Adebahr, S.
    Baltas, D.
    Brunner, T.
    Grosu, A. L.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S551 - S551
  • [34] Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer
    Amestoy, Frederic
    Roubaud, Guilhem
    Antoine, Mikael
    Fonteyne, Valerie
    Baumann, Brian C.
    Christodouleas, John
    Roupret, Morgan
    Azria, David
    Zilli, Thomas
    Hennequin, Christophe
    Xylinas, Evanguelos
    Sargos, Paul
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 142 : 76 - 85
  • [35] INTRABEAM: precision hypo-fractionated radiotherapy with a systemic immune response.
    Linares, I.
    Berenguer, M. A.
    Martinez, E.
    Laplana, M.
    Canas, R.
    Comas, S.
    Perez-Montero, H.
    Ventura, M.
    Guedea, F.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S596 - S596
  • [36] CLINICAL PROGRESS AND SURVIVAL OF PATIENTS WITH GLIOBLASTOMA AFTER HYPO-FRACTIONATED RADIOTHERAPY
    Jakes, A. D.
    Boyer, M.
    Hatfield, P.
    NEURO-ONCOLOGY, 2014, 16
  • [37] Outcomes and Predictive Factors in Large Hepatocellular Carcinoma Managed with Image-Guided Hypo-Fractionated Radiotherapy
    Kumar, R.
    Neibart, S. S.
    Kim, J.
    Mamidanna, S.
    Cui, T.
    Deek, M. P.
    Jabbour, S. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E458 - E459
  • [38] Hypo-fractionated stereotactic radiotherapy of five fractions with linear accelerator for vestibular schwannomas: A systematic review and meta-analysis
    Thien Nguyen
    Duong, Courtney
    Sheppard, John P.
    Lee, Seung Jin
    Kishan, Amar U.
    Lee, Percy
    Tenn, Stephen
    Chin, Robert
    Kaprealian, Tania B.
    Yang, Isaac
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2018, 166 : 116 - 123
  • [39] A Feasibility Study and Optimization of Dosimetric Objective with Heterogeneity Corrections for RTOG Studies with Hypo-fractionated Stereotactic Radiotherapy of Lung Cancers
    Harrison, A. S.
    Anamalayil, S.
    Timmerman, R.
    Straube, W.
    Bosch, W.
    Michalski, J.
    Galvin, J.
    Xiao, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S684 - S684
  • [40] Hypo-fractionated radiotherapy in elderly bladder cancer patients unfit for trimodal therapy
    Kraja, F.
    Janko, A.
    Hoti, A.
    Tole, E.
    Karaulli, E.
    Xhani, R.
    Hoxha, E.
    Kreka, B.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1240 - S1241